Masaomi Nangaku

List of Publications by Year in Descending Order

366 papers	15,503 citations	69 h-index	112 g-index
470 ext. papers	18,232 ext. citations	6.1 avg, IF	6.87 L-index

#	Paper	IF	Citations
366	SGLT2 inhibition in chronic kidney disease: a preventive strategy against acute kidney injury at the same time?. *Kidney International*, **2022**, 101, 20-22	9.9	
365	Oxidized alkyl phospholipids stimulate sodium transport in proximal tubules via a non-genomic PPAR□dependent pathway.. *Journal of Biological Chemistry*, **2022**, 101681	5.4	
364	Association Between Diabetes and Major Bleeding Complications of Renal Biopsy.. *Kidney International Reports*, **2022**, 7, 232-240	4.1	0
363	TRPM2 Plays a Minor Role in AKI and Kidney Fibrosis.. *Kidney360*, **2022**, 3, 153-157	1.8	0
362	Change in Cardiovascular Health Metrics and Risk for Proteinuria Development: Analysis of a Nationwide Population-Based Database.. *American Journal of Nephrology*, **2022**, 1-9	4.6	1
361	Thyroid hormone increases oxygen metabolism causing intrarenal tissue hypoxia; a pathway to kidney disease.. *PLoS ONE*, **2022**, 17, e0264524	3.7	0
360	Impact of Glucose Tolerance and Its Change on Incident Proteinuria: Analysis of a Nationwide Population-Based Dataset.. *American Journal of Nephrology*, **2022**, 1-9	4.6	0
359	Effect of Information and Communication Technology-Based Self-management System DialBeticsLite on Treating Abdominal Obesity in the Specific Health Guidance in Japan: Randomized Controlled Trial.. *JMIR Formative Research*, **2022**, 6, e33852	2.5	0
358	Lysine demethylase 2B regulates angiogenesis via Jumonji C dependent suppression of angiogenic transcription factors.. *Biochemical and Biophysical Research Communications*, **2022**, 605, 16-23	3.4	
357	Antibody recognition of complement Factor H reveals a flexible loop involved in Atypical Hemolytic Uremic Syndrome pathogenesis.. *Journal of Biological Chemistry*, **2022**, 101962	5.4	0
356	Impact of COVID-19 pandemic on healthcare service use for non-COVID-19 patients in Japan: retrospective cohort study.. *BMJ Open*, **2022**, 12, e060390	3	1
355	Resistance to Erythropoiesis-Stimulating Agents among Patients on Hemodialysis Is Typically Transient.. *American Journal of Nephrology*, **2022**, 1-10	4.6	0
354	Vadadustat for anemia in chronic kidney disease patients on peritoneal dialysis: A phase 3 open-label study in Japan. *Therapeutic Apheresis and Dialysis*, **2021**, 25, 642-653	1.9	10
353	Real-World Safety and Effectiveness of Canagliflozin Treatment for Type□2 Diabetes Mellitus in Japan: SAPPHIRE, a Long-Term, Large-Scale Post-Marketing Surveillance. *Advances in Therapy*, **2021** , 39, 674	4.1	1
352	Lysophosphatidylcholine mediates fast decline in kidney function in diabetic kidney disease. *Kidney International*, **2021**,	9.9	4
351	Effect of Digital Health Among People With Type 2 Diabetes Mellitus During the COVID-19 Pandemic in Japan. *Journal of Diabetes Science and Technology*, **2021**, 19322968211050040	4.1	
350	An evaluation of roxadustat for the treatment of anemia associated with chronic kidney disease. *Expert Opinion on Pharmacotherapy*, **2021**, 1-10	4	3

349	Altered Thyroid Function Tests Observed in Hypophosphatasia Patients Treated with Asfotase Alfa. *International Journal of Endocrinology*, **2021**, 2021, 5492267	2.7	
348	A distinctive distribution of hypoxia-inducible factor-1 in cultured renal tubular cells with hypoperfusion simulated by coverslip placement. *Physiological Reports*, **2021**, 9, e14689	2.6	
347	Activation of Sympathetic Signaling in Macrophages Blocks Systemic Inflammation and Protects against Renal Ischemia-Reperfusion Injury. *Journal of the American Society of Nephrology: JASN*, **2021**,	12.7	2
346	Phase 3 Randomized Study Comparing Vadadustat with Darbepoetin Alfa for Anemia in Japanese Patients with Nondialysis-Dependent CKD. *Journal of the American Society of Nephrology: JASN*, **2021**,	12.7	4
345	Incidence of Complications in 25 Adult Patients With X-linked Hypophosphatemia. *Journal of Clinical Endocrinology and Metabolism*, **2021**, 106, e3682-e3692	5.6	3
344	Nationwide survey of the coronavirus disease 2019 prevention and treatment systems for kidney disease patients: a study of Japanese Society of Nephrology-certified educational facilities. *Clinical and Experimental Nephrology*, **2021**, 25, 996-1002	2.5	0
343	Infection prevention measures for patients undergoing hemodialysis during the COVID-19 pandemic in Japan: a nationwide questionnaire survey. *Renal Replacement Therapy*, **2021**, 7, 27	2.3	4
342	Regional Distribution of Cardiologists and Prescription Patterns of Sodium-Glucose Transporter-2 Inhibitors in Japan. *International Heart Journal*, **2021**, 62, 592-600	1.8	1
341	Efficacy and safety of daprodustat in Japanese peritoneal dialysis patients. *Therapeutic Apheresis and Dialysis*, **2021**, 25, 979-987	1.9	0
340	Immune checkpoint inhibitor combination therapies very frequently induce secondary adrenal insufficiency. *Scientific Reports*, **2021**, 11, 11617	4.9	1
339	Efficacy and safety of esaxerenone (CS-3150) in Japanese patients with type 2 diabetes and macroalbuminuria: a multicenter, single-arm, open-label phase III study. *Clinical and Experimental Nephrology*, **2021**, 25, 1070-1078	2.5	4
338	Does a preclinical randomized controlled trial, pRCT, resolve the gap between animal studies and human trials?. *Kidney International*, **2021**, 99, 1262-1264	9.9	1
337	Factors associated with long-term care certification in older adults: a cross-sectional study based on a nationally representative survey in Japan. *BMC Geriatrics*, **2021**, 21, 374	4.1	1
336	A Phase 3 Study of Enarodustat in Anemic Patients with CKD not Requiring Dialysis: The SYMPHONY ND Study. *Kidney International Reports*, **2021**, 6, 1840-1849	4.1	2
335	Preexisting heart failure with reduced ejection fraction attenuates renal fibrosis after ischemia reperfusion via sympathetic activation. *Scientific Reports*, **2021**, 11, 15091	4.9	0
334	A Phase 3 Study of Enarodustat (JTZ-951) in Japanese Hemodialysis Patients for Treatment of Anemia in Chronic Kidney Disease: SYMPHONY HD Study.. *Kidney Diseases (Basel, Switzerland)*, **2021** , 7, 494-502	3.3	2
333	Comparison of fracture risk between proton pump inhibitors and histamine-2 receptor antagonists in ANCA-associated vasculitis patients: a nested case-control study. *Rheumatology*, **2021**, 60, 1717-1723	3.9	2
332	Recommendations by the Asian Pacific society of nephrology (APSN) on the appropriate use of HIF-PH inhibitors. *Nephrology*, **2021**, 26, 105-118	2.2	21

331	Initial responsiveness to darbepoetin alfa and its contributing factors in non-dialysis chronic kidney disease patients in Japan. *Clinical and Experimental Nephrology*, **2021**, 25, 110-119	2.5	3
330	Multifactorial intervention has a significant effect on diabetic kidney disease in patients with type 2 diabetes. *Kidney International*, **2021**, 99, 256-266	9.9	14
329	The Future of Nephrology and Public Health. *Contributions To Nephrology*, **2021**, 199, 339-350	1.6	3
328	Treatment of Diabetic Kidney Disease: Current and Future. *Diabetes and Metabolism Journal*, **2021**, 45, 11-26	5	24
327	Aging-Related Kidney Diseases. *Contributions To Nephrology*, **2021**, 199, 266-273	1.6	1
326	Association between nutritional guidance or ophthalmological examination and discontinuation of physician visits in patients with newly diagnosed diabetes: A retrospective cohort study using a nationwide database. *Journal of Diabetes Investigation*, **2021**, 12, 1619-1631	3.9	0
325	Profile of Daprodustat in the Treatment of Renal Anemia Due to Chronic Kidney Disease. *Therapeutics and Clinical Risk Management*, **2021**, 17, 155-163	2.9	4
324	Daprodustat Compared with Epoetin Beta Pegol for Anemia in Japanese Patients Not on Dialysis: A 52-Week Randomized Open-Label Phase 3 Trial. *American Journal of Nephrology*, **2021**, 52, 26-35	4.6	12
323	Update on diagnosis, pathophysiology, and management of diabetic kidney disease. *Nephrology*, **2021**, 26, 491-500	2.2	14
322	Efficacy and safety of vadadustat compared with darbepoetin alfa in Japanese anemic patients on hemodialysis: a Phase 3, multicenter, randomized, double-blind study. *Nephrology Dialysis Transplantation*, **2021**, 36, 1731-1741	4.3	8
321	Clinical Characteristics and Incidences of Benign and Malignant Insulinoma Using a National Inpatient Database in Japan. *Journal of Clinical Endocrinology and Metabolism*, **2021**, 106, 3477-3486	5.6	0
320	Efficacy of the Self-management Support System DialBetesPlus for Diabetic Kidney Disease: Protocol for a Randomized Controlled Trial. *JMIR Research Protocols*, **2021**, 10, e31061	2	1
319	Performance evaluation of the new chemiluminescent intact FGF23 assay relative to the existing assay system. *Journal of Bone and Mineral Metabolism*, **2021**, 1	2.9	2
318	A novel method for successful induction of interdigitating process formation in conditionally immortalized podocytes from mice, rats, and humans. *Biochemical and Biophysical Research Communications*, **2021**, 570, 47-52	3.4	1
317	Decreased IFT88 expression with primary cilia shortening causes mitochondrial dysfunction in cisplatin-induced tubular injury. *American Journal of Physiology - Renal Physiology*, **2021**, 321, F278-F292	4.3	2
316	Two long-term phase 3 studies of enarodustat (JTZ-951) in Japanese anemic patients with chronic kidney disease not on dialysis or on maintenance hemodialysis: SYMPHONY ND-Long and HD-Long studies. *Therapeutic Apheresis and Dialysis*, **2021**,	1.9	1
315	Potassium Concentration in Initial Fluid Therapy and In-Hospital Mortality of Patients with Diabetic Ketoacidosis. *Journal of Clinical Endocrinology and Metabolism*, **2021**, 106, e2162-e2175	5.6	0
314	4. Oxygen Sensing Mechanisms and Nobel Prize. *The Journal of the Japanese Society of Internal Medicine*, **2021**, 110, 77a-80a	0	

313	V. AKI to CKD - Transitional Mechanisms from AKI to CKD. *The Journal of the Japanese Society of Internal Medicine*, **2021**, 110, 928-934	0	
312	New insights into tubular cell recovery after ischemic acute kidney injury. *Kidney International*, **2020**, 97, 845-846	9.9	
311	Prolyl Hydroxylase Domain Inhibitor Protects against Metabolic Disorders and Associated Kidney Disease in Obese Type 2 Diabetic Mice. *Journal of the American Society of Nephrology: JASN*, **2020**, 31, 560-577	12.7	30
310	A cellular model of albumin endocytosis uncovers a link between membrane and nuclear proteins. *Journal of Cell Science*, **2020**, 133,	5.3	1
309	Hypoxia-inducible factor prolyl hydroxylase inhibitor in the treatment of anemia in chronic kidney disease. *Current Opinion in Nephrology and Hypertension*, **2020**, 29, 414-422	3.5	6
308	Randomized Clinical Trial on the Effect of Bardoxolone Methyl on GFR in Diabetic Kidney Disease Patients (TSUBAKI Study). *Kidney International Reports*, **2020**, 5, 879-890	4.1	37
307	COVID-19 of dialysis patients in Japan: Current status and guidance on preventive measures. *Therapeutic Apheresis and Dialysis*, **2020**, 24, 361-365	1.9	28
306	Vagus nerve stimulation even after injury ameliorates cisplatin-induced nephropathy via reducing macrophage infiltration. *Scientific Reports*, **2020**, 10, 9472	4.9	8
305	Podocyte-specific deletion of tubular sclerosis complex 2 promotes focal segmental glomerulosclerosis and progressive renal failure. *PLoS ONE*, **2020**, 15, e0229397	3.7	1
304	Coordinated demethylation of H3K9 and H3K27 is required for rapid inflammatory responses of endothelial cells. *EMBO Journal*, **2020**, 39, e103949	13	23
303	The role of hypoxia in the pathogenesis of lupus nephritis. *Kidney International*, **2020**, 98, 821-823	9.9	1
302	Global case studies for chronic kidney disease/end-stage kidney disease care. *Kidney International Supplements*, **2020**, 10, e24-e48	6.3	25
301	Recombinant thrombomodulin prevents acute lung injury induced by renal ischemia-reperfusion injury. *Scientific Reports*, **2020**, 10, 289	4.9	18
300	Outcomes of lactulose plus branched-chain amino acid infusion and lactulose alone for hepatic encephalopathy: A retrospective cohort study using a national inpatient database. *Hepatology Research*, **2020**, 50, 693-703	5.1	3
299	Correlation between the Incidence and Attributable Mortality Fraction of Acute Kidney Injury: A Systematic Review. *Blood Purification*, **2020**, 49, 386-393	3.1	1
298	Conditions, pathogenesis, and progression of diabetic kidney disease and early decliner in Japan. *BMJ Open Diabetes Research and Care*, **2020**, 8,	4.5	13
297	Regional variance in the use of urine dipstick test for outpatients in Japan. *Nephrology*, **2020**, 25, 676-682	2.2	0
296	Using mHealth to Provide Mobile App Users With Visualization of Health Checkup Data and Educational Videos on Lifestyle-Related Diseases: Methodological Framework for Content Development. *JMIR MHealth and UHealth*, **2020**, 8, e20982	5.5	4

295	Regional Variance of the Early Use of Tolvaptan for Autosomal Dominant Polycystic Kidney Disease.. *Kidney360*, **2020**, 1, 740-745	1.8	2
294	Willingness of Patients Prescribed Medications for Lifestyle-Related Diseases to Use Personal Health Records: Questionnaire Study. *Journal of Medical Internet Research*, **2020**, 22, e13866	7.6	2
293	Profiles of Coagulation and Fibrinolysis Activation-Associated Molecular Markers of Atypical Hemolytic Uremic Syndrome in the Acute Phase. *Journal of Atherosclerosis and Thrombosis*, **2020**, 27, 353-362	4	7
292	Modulating the immune system to delay the clinical onset of type 1 diabetes. *Kidney International*, **2020**, 97, 248-250	9.9	
291	JTZ-951, an HIF prolyl hydroxylase inhibitor, suppresses renal interstitial fibroblast transformation and expression of fibrosis-related factors. *American Journal of Physiology - Renal Physiology*, **2020**, 318, F14-F24	4.3	12
290	The oral hypoxia-inducible factor prolyl hydroxylase inhibitor enarodustat counteracts alterations in renal energy metabolism in the early stages of diabetic kidney disease. *Kidney International*, **2020**, 97, 934-950	9.9	36
289	Effects of a prolyl hydroxylase inhibitor on kidney and cardiovascular complications in a rat model of chronic kidney disease. *American Journal of Physiology - Renal Physiology*, **2020**, 318, F388-F401	4.3	18
288	Nuclear factor erythroid 2-related factor 2 as a treatment target of kidney diseases. *Current Opinion in Nephrology and Hypertension*, **2020**, 29, 128-135	3.5	16
287	Prolyl hydroxylase inhibition protects the kidneys from ischemia via upregulation of glycogen storage. *Kidney International*, **2020**, 97, 687-701	9.9	27
286	The role of anti-complement factor H antibodies in the development of atypical haemolytic uremic syndrome: a possible contribution to abnormality of platelet function. *British Journal of Haematology*, **2020**, 189, 182-186	4.5	3
285	More reasons to use SGLT2 inhibitors: EMPEROR-reduced and DAPA-CKD. *Kidney International*, **2020**, 98, 1387-1389	9.9	3
284	International consensus definitions of clinical trial outcomes for kidney failure: 2020. *Kidney International*, **2020**, 98, 849-859	9.9	19
283	Hierarchical Clustering Analysis for Predicting 1-Year Mortality After Starting Hemodialysis. *Kidney International Reports*, **2020**, 5, 1188-1195	4.1	6
282	Esaxerenone (CS-3150) in Patients with Type 2 Diabetes and Microalbuminuria (ESAX-DN): Phase 3 Randomized Controlled Clinical Trial. *Clinical Journal of the American Society of Nephrology: CJASN*, **2020**, 15, 1715-1727	6.9	28
281	Lysine demethylase 7a regulates murine anterior-posterior development by modulating the transcription of Hox gene cluster. *Communications Biology*, **2020**, 3, 725	6.7	1
280	Association Between IV Thiamine and Mortality in Patients With Septic Shock: A Nationwide Observational Study. *Critical Care Medicine*, **2020**, 48, 1135-1139	1.4	12
279	Intracellular calcium response of primary cilia of tubular cells to modulated shear stress under oxidative stress. *Biomicrofluidics*, **2020**, 14, 044102	3.2	0
278	Hypoxia-Inducible Factor and Oxygen Biology in the Kidney.. *Kidney360*, **2020**, 1, 1021-1031	1.8	3

277	Different Biomarker Kinetics in Critically Ill Patients with High Lactate Levels. *Diagnostics*, **2020**, 10,	3.8	1
276	Vadadustat, an oral hypoxia-inducible factor prolyl hydroxylase inhibitor, for treatment of anemia of chronic kidney disease: two randomized Phase 2 trials in Japanese patients. *Nephrology Dialysis Transplantation*, **2020**,	4.3	15
275	Efficacy and Safety of Daprodustat Compared with Darbepoetin Alfa in Japanese Hemodialysis Patients with Anemia: A Randomized, Double-Blind, Phase 3 Trial. *Clinical Journal of the American Society of Nephrology: CJASN*, **2020**, 15, 1155-1165	6.9	33
274	Inverse Correlation Between Incidence and Mortality of Acute Kidney Injury in Critically Ill Patients: A Systematic Review. *Shock*, **2020**, 54, 280-284	3.4	2
273	Low rather than high mean corpuscular volume is associated with mortality in Japanese patients under hemodialysis. *Scientific Reports*, **2020**, 10, 15663	4.9	0
272	A disposable, ultra-fine endoscope for non-invasive, close examination of the intraluminal surface of the peritoneal dialysis catheter and peritoneal cavity. *Scientific Reports*, **2020**, 10, 17565	4.9	
271	Expanded Indication for Recombinant Tissue Plasminogen Activator from 3 to 4.5 h after Onset of Stroke in Japan. *Journal of Stroke and Cerebrovascular Diseases*, **2020**, 29, 105341	2.8	2
270	Urinary Neutrophil Gelatinase-Associated Lipocalin in Critically Ill Patients With Coronavirus Disease 2019 **2020**, 2, e0181		5
269	Schl□dorff and Lee revealed crosstalk between glomerular cells and a role of BAMBI in diabetic kidney disease. *Kidney International*, **2020**, 98, 539-541	9.9	
268	Insulin promotes sodium transport but suppresses gluconeogenesis via distinct cellular pathways in□human and rat renal proximal tubules. *Kidney International*, **2020**, 97, 316-326	9.9	8
267	Munc18-1-interacting protein 3 mitigates renal fibrosis through protection of tubular epithelial cells from apoptosis. *Nephrology Dialysis Transplantation*, **2020**, 35, 576-586	4.3	2
266	Darbepoetin Alfa in Patients with Advanced CKD without Diabetes: Randomized, Controlled Trial. *Clinical Journal of the American Society of Nephrology: CJASN*, **2020**, 15, 608-615	6.9	7
265	Association between intravenous contrast media exposure and non-recovery from dialysis-requiring septic acute kidney injury: a nationwide observational study. *Intensive Care Medicine*, **2019**, 45, 1570-1579	14.5	9
264	New measures against chronic kidney diseases in Japan since 2018. *Clinical and Experimental Nephrology*, **2019**, 23, 1263-1271	2.5	7
263	Non-canonical cholinergic anti-inflammatory pathway-mediated activation of peritoneal macrophages induces Hes1 and blocks ischemia/reperfusion injury in the kidney. *Kidney International*, **2019**, 95, 563-576	9.9	26
262	A Placebo-Controlled, Randomized Trial of Enarodustat in Patients with Chronic Kidney Disease Followed by Long-Term Trial. *American Journal of Nephrology*, **2019**, 49, 165-174	4.6	43
261	Are SGLT2 inhibitors a targeted treatment for diabetic kidney disease?. *Kidney International*, **2019**, 96, 8-10	9.9	4
260	Enarodustat, Conversion and Maintenance Therapy for Anemia in Hemodialysis Patients: A Randomized, Placebo-Controlled Phase 2b Trial Followed by Long-Term Trial. *Nephron*, **2019**, 143, 77-85	3.3	28

259	Effectiveness and safety of cinacalcet for primary hyperparathyroidism: a single center experience. *Endocrine Journal*, **2019**, 66, 683-689	2.9	5
258	Temporal change in characteristics and outcomes of acute kidney injury on renal replacement therapy in intensive care units: analysis of a nationwide administrative database in Japan, 2007-2016. *Critical Care*, **2019**, 23, 172	10.8	11
257	In vivo rendezvous of small nucleic acid drugs with charge-matched block catiomers to target cancers. *Nature Communications*, **2019**, 10, 1894	17.4	34
256	Comprehensive three-dimensional analysis (CUBIC-kidney) visualizes abnormal renal sympathetic nerves after ischemia/reperfusion injury. *Kidney International*, **2019**, 96, 129-138	9.9	22
255	Hypoxia-Inducible Factor-Prolyl Hydroxylase Domain Inhibitors to Treat Anemia in Chronic Kidney Disease. *Contributions To Nephrology*, **2019**, 198, 112-123	1.6	18
254	Molecular analysis and literature-based hypothesis of an immunonegative prostate small cell carcinoma causing ectopic ACTH syndrome. *Endocrine Journal*, **2019**, 66, 547-554	2.9	1
253	Inhibition of prolyl hydroxylase domain (PHD) by JTZ-951 reduces obesity-related diseases in the liver, white adipose tissue, and kidney in mice with a high-fat diet. *Laboratory Investigation*, **2019**, 99, 1217-1232	5.9	22
252	Tocilizumab for focal segmental glomerulosclerosis secondary to multicentric Castleman disease. *Annals of Hematology*, **2019**, 98, 1995-1997	3	1
251	Safety and effectiveness of eculizumab for pediatric patients with atypical hemolytic-uremic syndrome in Japan: interim analysis of post-marketing surveillance. *Clinical and Experimental Nephrology*, **2019**, 23, 112-121	2.5	12
250	Safety and effectiveness of eculizumab for adult patients with atypical hemolytic-uremic syndrome in Japan: interim analysis of post-marketing surveillance. *Clinical and Experimental Nephrology*, **2019**, 23, 65-75	2.5	7
249	JTZ-951 (enarodustat), a hypoxia-inducibe factor prolyl hydroxylase inhibitor, stabilizes HIF- protein and induces erythropoiesis without effects on the function of vascular endothelial growth factor. *European Journal of Pharmacology*, **2019**, 859, 172532	5.3	21
248	Efficacy and Safety of Esaxerenone (CS-3150) for the Treatment of Type 2 Diabetes with Microalbuminuria: A Randomized, Double-Blind, Placebo-Controlled, Phase II Trial. *Clinical Journal of the American Society of Nephrology: CJASN*, **2019**, 14, 1161-1172	6.9	45
247	Novel Hybrid in C3 Glomerulopathy Identified by Genomic Structural Variation Analysis. *Kidney International Reports*, **2019**, 4, 1759-1762	4.1	1
246	Podocyte lipotoxicity in diabetic kidney disease. *Kidney International*, **2019**, 96, 809-812	9.9	9
245	Mitochondrial Damage Causes Inflammation via cGAS-STING Signaling in Acute Kidney Injury. *Cell Reports*, **2019**, 29, 1261-1273.e6	10.6	106
244	Increased albuminuria in bardoxolone methyl-treated type 2 diabetes patients: mere reflection of eGFR improvement?. *Kidney International*, **2019**, 96, 823-825	9.9	2
243	Usage Patterns of GlucoNote, a Self-Management Smartphone App, Based on ResearchKit for Patients With Type 2 Diabetes and Prediabetes. *JMIR MHealth and UHealth*, **2019**, 7, e13204	5.5	16
242	The role of oxidative stress and hypoxia in renal disease. *Kidney Research and Clinical Practice*, **2019**, 38, 414-426	3.6	52

241	Atypical Hemolytic Uremic Syndrome With the p.Ile1157Thr C3 Mutation Successfully Treated With Plasma Exchange and Eculizumab: A Case Report **2019**, 1, e0008		2
240	Extraperitoneal Placement of a Peritoneal Dialysis Catheter. *Internal Medicine*, **2019**, 58, 147-148	1.1	
239	Safety and effectiveness of long-term use of darbepoetin alfa in non-dialysis patients with chronic kidney disease: a post-marketing surveillance study in Japan. *Clinical and Experimental Nephrology*, **2019**, 23, 231-243	2.5	8
238	Pathogenesis of Atypical Hemolytic Uremic Syndrome. *Journal of Atherosclerosis and Thrombosis*, **2019**, 26, 99-110	4	29
237	Empagliflozin and kidney outcomes in Asian patients with type 2 diabetes and established cardiovascular disease: Results from the EMPA-REG OUTCOME trial. *Journal of Diabetes Investigation*, **2019**, 10, 760-770	3.9	36
236	Tipping the Balance from Angiogenesis to Fibrosis in Chronic Kidney Disease. *Molecular and Translational Medicine*, **2019**, 419-449	0.4	
235	Regulatory roles of hypoxia-inducible, noncoding RNAs on mitochondrial dynamics during AKI. *Kidney International*, **2019**, 95, 252-253	9.9	1
234	ATF6 downregulation of PPAR promotes lipotoxicity-induced tubulointerstitial fibrosis. *Kidney International*, **2019**, 95, 577-589	9.9	45
233	Kinetic estimated glomerular filtration rate as a predictor of successful continuous renal replacement therapy discontinuation. *Nephrology*, **2019**, 24, 287-293	2.2	13
232	Genome-wide analysis revealed that DZNep reduces tubulointerstitial fibrosis via down-regulation of pro-fibrotic genes. *Scientific Reports*, **2018**, 8, 3779	4.9	11
231	Intravital phosphorescence lifetime imaging of the renal cortex accurately measures renal hypoxia. *Kidney International*, **2018**, 93, 1483-1489	9.9	25
230	Modest Impact of Serial Measurements of Acute Kidney Injury Biomarkers in an Adult Intensive Care Unit. *Nephron*, **2018**, 139, 243-253	3.3	4
229	H-ATPase blockade reduced renal gluconeogenesis and plasma glucose in a diabetic rat model. *Medical Molecular Morphology*, **2018**, 51, 89-95	2.3	4
228	Controversies of the classification of TMA and the terminology of aHUS. *Clinical and Experimental Nephrology*, **2018**, 22, 979-980	2.5	4
227	Glomeruloid hemangioma associated with TAFRO syndrome. *Human Pathology*, **2018**, 82, 172-176	3.7	4
226	Functional splicing analysis in an infantile case of atypical hemolytic uremic syndrome caused by digenic mutations in C3 and MCP genes. *Journal of Human Genetics*, **2018**, 63, 755-759	4.3	6
225	Clinical characteristics and genetic backgrounds of Japanese patients with atypical hemolytic uremic syndrome. *Clinical and Experimental Nephrology*, **2018**, 22, 1088-1099	2.5	24
224	Urinary N-acetyl- glucosaminidase and estimated Glomerular filtration rate may identify patients to be treated with immuno-suppression at diagnosis in idiopathic membranous nephropathy. *Nephrology*, **2018**, 23, 175-182	2.2	4

223	Rationale and design of oBservational clinical Research In chronic kidney disease patients with renal anemia: renal proGnosis in patients with Hyporesponsive anemia To Erythropoiesis-stimulating agents, darbepoetiN alfa (BRIGHTEN Trial). *Clinical and Experimental Nephrology*, **2018**, 22, 78-84	2.5	3
222	Pulmonary nonsegmental micronodules in a patient undergoing hemodialysis. *Clinical and Experimental Nephrology*, **2018**, 22, 201-202	2.5	
221	Diabetic Kidney Disease **2018**, 1-17		1
220	Importance of glomerular filtration rate change as surrogate endpoint for the future incidence of end-stage renal disease in general Japanese population: community-based cohort study. *Clinical and Experimental Nephrology*, **2018**, 22, 318-327	2.5	21
219	Guidelines for clinical evaluation of chronic kidney disease : AMED research on regulatory science of pharmaceuticals and medical devices. *Clinical and Experimental Nephrology*, **2018**, 22, 1446-1475	2.5	13
218	Prognostic factors of Erdheim-Chester disease: a nationwide survey in Japan. *Haematologica*, **2018**, 103, 1815-1824	6.6	15
217	Sodium-glucose cotransporter 2 inhibition normalizes glucose metabolism and suppresses oxidative stress in the kidneys of diabetic mice. *Kidney International*, **2018**, 94, 912-925	9.9	70
216	Hypoxia-inducible factor stabilizers for treating anemia of chronic kidney disease. *Current Opinion in Nephrology and Hypertension*, **2018**, 27, 331-338	3.5	27
215	Palmitate deranges erythropoietin production via transcription factor ATF4 activation of unfolded protein response. *Kidney International*, **2018**, 94, 536-550	9.9	17
214	Observation period for changes in proteinuria and risk prediction of end-stage renal disease in general population. *Nephrology*, **2018**, 23, 821-829	2.2	13
213	Damage-associated molecular patterns in intensive care unit patients with acute liver injuries: A prospective cohort study. *Medicine (United States)*, **2018**, 97, e12780	1.8	2
212	Targeting oxidative stress in diabetic kidney disease: a novel drug in an old pathway. *Kidney International*, **2018**, 94, 1038-1039	9.9	2
211	Efficacy of a novel inhibitor of vascular adhesion protein-1 in reducing albuminuria in patients with diabetic kidney disease (ALBUM): a randomised, placebo-controlled, phase 2 trial. *Lancet Diabetes and Endocrinology,the*, **2018**, 6, 925-933	18.1	20
210	Mechanisms of metabolic memory and renal hypoxia as a therapeutic target in diabetic kidney disease. *Journal of Diabetes Investigation*, **2017**, 8, 261-271	3.9	27
209	Oxygen imaging of living cells and tissues using luminescent molecular probes. *Journal of Photochemistry and Photobiology C: Photochemistry Reviews*, **2017**, 30, 71-95	16.4	65
208	Effects of Daprodustat, a Novel Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor on Anemia Management in Japanese Hemodialysis Subjects. *American Journal of Nephrology*, **2017**, 45, 127-135	4.6	66
207	Applications of the CRISPR-Cas9 system in kidney research. *Kidney International*, **2017**, 92, 324-335	9.9	9
206	Global kidney health 2017 and beyond: a roadmap for closing gaps in care, research, and policy. *Lancet, The*, **2017**, 390, 1888-1917	40	419

205	ACE2 as therapy for glomerular disease: the devil is in the detail. *Kidney International*, **2017**, 91, 1269-1271	9.9	11
204	Novel lnc RNA regulated by HIF-1 inhibits apoptotic cell death in the renal tubular epithelial cells under hypoxia. *Physiological Reports*, **2017**, 5, e13203	2.6	23
203	Dual Regulation of Gluconeogenesis by Insulin and Glucose in the Proximal Tubules of the Kidney. *Diabetes*, **2017**, 66, 2339-2350	0.9	44
202	Vascular adhesion protein-1 enhances neutrophil infiltration by generation of hydrogen peroxide in renal ischemia/reperfusion injury. *Kidney International*, **2017**, 92, 154-164	9.9	27
201	Previous dropout from diabetic care as a predictor of patients' willingness to use mobile applications for self-management: A cross-sectional study. *Journal of Diabetes Investigation*, **2017**, 8, 542-549	3.9	9
200	Mitochondrial Abnormality Facilitates Cyst Formation in Autosomal Dominant Polycystic Kidney Disease. *Molecular and Cellular Biology*, **2017**, 37,	4.8	67
199	Targeting gene expression to specific cells of kidney tubules in vivo, using adenoviral promoter fragments. *PLoS ONE*, **2017**, 12, e0168638	3.7	9
198	Complications of chronic kidney disease: current state, knowledge gaps, and strategy for action. *Kidney International Supplements*, **2017**, 7, 122-129	6.3	55
197	D-serine, a novel uremic toxin, induces senescence in human renal tubular cells via GCN2 activation. *Scientific Reports*, **2017**, 7, 11168	4.9	22
196	Echinomycin inhibits adipogenesis in 3T3-L1 cells in a HIF-independent manner. *Scientific Reports*, **2017**, 7, 6516	4.9	22
195	Epigenetic Changes in the Acute Kidney Injury-to-Chronic Kidney Disease Transition. *Nephron*, **2017**, 137, 256-259	3.3	21
194	Prolyl hydroxylase domain inhibitors as a novel therapeutic approach against anemia in chronic kidney disease. *Kidney International*, **2017**, 92, 306-312	9.9	66
193	2015 Japanese Society for Dialysis Therapy: Guidelines for Renal Anemia in Chronic Kidney Disease. *Renal Replacement Therapy*, **2017**, 3,	2.3	99
192	Heterogeneity of clinical indices among the older dialysis population: study on Japanese dialysis population. *Renal Replacement Therapy*, **2017**, 3,	2.3	6
191	Mizoribine therapy combined with steroids and mizoribine blood concentration monitoring for idiopathic membranous nephropathy with steroid-resistant nephrotic syndrome. *Clinical and Experimental Nephrology*, **2017**, 21, 961-970	2.5	8
190	The Longitudinal Study of Liver Cysts in Patients With Autosomal Dominant Polycystic Kidney Disease and Polycystic Liver Disease. *Kidney International Reports*, **2017**, 2, 60-65	4.1	3
189	Renal Hypoxia in CKD; Pathophysiology and Detecting Methods. *Frontiers in Physiology*, **2017**, 8, 99	4.6	50
188	Testing the Feasibility and Usability of a Novel Smartphone-Based Self-Management Support System for Dialysis Patients: A Pilot Study. *JMIR Research Protocols*, **2017**, 6, e63	2	21

187	Rationale and study design of a randomized controlled trial to assess the effects of maintaining hemoglobin levels using darbepoetin alfa on prevention of development of end-stage kidney disease in non-diabetic CKD patients (PREDICT Trial). *Clinical and Experimental Nephrology*, **2016**, 20, 71-6	2.5	6
186	Hypoxia and hypoxia-inducible factors in chronic kidney disease. *Renal Replacement Therapy*, **2016**, 2,	2.3	13
185	New insights into molecular mechanisms of epigenetic regulation in kidney disease. *Clinical and Experimental Pharmacology and Physiology*, **2016**, 43, 1159-1167	3	13
184	Impact of clinical context on acute kidney injury biomarker performances: differences between neutrophil gelatinase-associated lipocalin and L-type fatty acid-binding protein. *Scientific Reports*, **2016**, 6, 33077	4.9	12
183	Analysis of the V2 Vasopressin Receptor (V2R) Mutations Causing Partial Nephrogenic Diabetes Insipidus Highlights a Sustainable Signaling by a Non-peptide V2R Agonist. *Journal of Biological Chemistry*, **2016**, 291, 22460-22471	5.4	13
182	Clinical guides for atypical hemolytic uremic syndrome in Japan. *Clinical and Experimental Nephrology*, **2016**, 20, 536-543	2.5	28
181	No association between dysplasminogenemia with p.Ala620Thr mutation and atypical hemolytic uremic syndrome. *International Journal of Hematology*, **2016**, 104, 223-7	2.3	6
180	Correction of Metabolic Alkalosis and Elevated Calcium Levels by Sodium Chloride in a Hemodialysis Patient With Inadequate Chloride Intake. *Therapeutic Apheresis and Dialysis*, **2016**, 20, 86-7	1.9	1
179	Interstitial renal fibrosis due to multiple cisplatin treatments is ameliorated by semicarbazide-sensitive amine oxidase inhibition. *Kidney International*, **2016**, 89, 374-85	9.9	45
178	The reduced expression of proximal tubular transporters in acquired Fanconi syndrome with light chain deposition. *Medical Molecular Morphology*, **2016**, 49, 48-52	2.3	2
177	Progression after AKI: Understanding Maladaptive Repair Processes to Predict and Identify Therapeutic Treatments. *Journal of the American Society of Nephrology: JASN*, **2016**, 27, 687-97	12.7	238
176	Erythropoietin concentration in acute kidney injury is associated with insulin-like growth factor-binding protein-1. *Nephrology*, **2016**, 21, 693-9	2.2	7
175	DialBetics: Smartphone-Based Self-Management for Type 2 Diabetes Patients on Insulin Injections. *Journal of Diabetes Science and Technology*, **2016**, 10, 804-5	4.1	6
174	Hypoxia-Inducible Factor-1 Activates the Transforming Growth Factor- SMAD3 Pathway in Kidney Tubular Epithelial Cells. *American Journal of Nephrology*, **2016**, 44, 276-285	4.6	34
173	Lactoferrin Suppresses Neutrophil Extracellular Traps Release in Inflammation. *EBioMedicine*, **2016**, 10, 204-15	8.8	81
172	Inflammation and hypoxia linked to renal injury by CCAAT/enhancer-binding protein *Kidney International*, **2015**, 88, 262-75	9.9	47
171	Prospective randomized study of the tolerability and efficacy of combination therapy for hypertensive chronic kidney disease: results of the PROTECT-CKD study. *Clinical and Experimental Nephrology*, **2015**, 19, 925-32	2.5	5
170	Glypican-5 Increases Susceptibility to Nephrotic Damage in Diabetic Kidney. *American Journal of Pathology*, **2015**, 185, 1889-98	5.8	13

169	Endothelin-converting enzyme is a plausible target gene for hypoxia-inducible factor. *Kidney International*, **2015**, 87, 761-70	9.9	15
168	Sirtuin1 Maintains Actin Cytoskeleton by Deacetylation of Cortactin in Injured Podocytes. *Journal of the American Society of Nephrology: JASN*, **2015**, 26, 1939-59	12.7	46
167	Activation of hypoxia-inducible factors prevents diabetic nephropathy. *Journal of the American Society of Nephrology: JASN*, **2015**, 26, 328-38	12.7	123
166	Phospholipase A2 receptor positive membranous nephropathy long after living donor kidney transplantation between identical twins. *Nephrology*, **2015**, 20 Suppl 2, 101-4	2.2	3
165	Arteriolar hyalinosis and arterial hypertension as possible surrogate markers of reduced interstitial blood flow and hypoxia in glomerulonephritis. *Nephrology*, **2015**, 20, 11-7	2.2	13
164	Angiotensin receptor blocker telmisartan suppresses renal gluconeogenesis during starvation. *Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy*, **2015**, 8, 103-13	3.4	14
163	High (≥6.5) Spontaneous and Persistent Urinary pH Is Protective of Renal Function at Baseline and during Disease Course in Idiopathic Membranous Nephropathy. *International Journal of Nephrology*, **2015**, 2015, 730234	1.7	
162	Recent advances in understanding of chronic kidney disease. *F1000Research*, **2015**, 4,	3.6	18
161	A circulating permeability factor in focal segmental glomerulosclerosis: the hunt continues. *CKJ: Clinical Kidney Journal*, **2015**, 8, 708-15	4.5	52
160	How the Target Hemoglobin of Renal Anemia Should Be. *Nephron*, **2015**, 131, 202-9	3.3	17
159	Hypoxia and Dysregulated Angiogenesis in Kidney Disease. *Kidney Diseases (Basel, Switzerland)*, **2015**, 1, 80-9	3.3	40
158	Role of uremic toxins in erythropoiesis-stimulating agent resistance in chronic kidney disease and dialysis patients. *Journal of Renal Nutrition*, **2015**, 25, 160-3	3	25
157	Regulation of Mitochondrial Dynamics by Dynamin-Related Protein-1 in Acute Cardiorenal Syndrome. *Journal of the American Society of Nephrology: JASN*, **2015**, 26, 2378-87	12.7	67
156	Adult stem-like cells in kidney. *World Journal of Stem Cells*, **2015**, 7, 490-4	5.6	12
155	Quantitating intracellular oxygen tension in vivo by phosphorescence lifetime measurement. *Scientific Reports*, **2015**, 5, 17838	4.9	33
154	Long-Term Pancreas Allograft Survival in Simultaneous Pancreas-Kidney Transplantation by Era. *Clinical Transplants*, **2015**, 31, 35-42		
153	Revolution of nephrology research by deep sequencing: ChIP-seq and RNA-seq. *Kidney International* , **2014**, 85, 31-8	9.9	31
152	Proteostasis in endoplasmic reticulum--new mechanisms in kidney disease. *Nature Reviews Nephrology*, **2014**, 10, 369-78	14.9	133

151	Diagnostic criteria for atypical hemolytic uremic syndrome proposed by the Joint Committee of the Japanese Society of Nephrology and the Japan Pediatric Society. *Clinical and Experimental Nephrology*, **2014**, 18, 4-9	2.5	19
150	The potential for renoprotection with incretin-based drugs. *Kidney International*, **2014**, 86, 701-11	9.9	77
149	Hypoxia as a key player in the AKI-to-CKD transition. *American Journal of Physiology - Renal Physiology*, **2014**, 307, F1187-95	4.3	143
148	Cross-enhancement of ANGPTL4 transcription by HIF1 alpha and PPAR beta/delta is the result of the conformational proximity of two response elements. *Genome Biology*, **2014**, 15, R63	18.3	40
147	Genome-wide analysis of murine renal distal convoluted tubular cells for the target genes of mineralocorticoid receptor. *Biochemical and Biophysical Research Communications*, **2014**, 445, 132-7	3.4	21
146	Evaluation of urinary tissue inhibitor of metalloproteinase-2 in acute kidney injury: a prospective observational study. *Critical Care*, **2014**, 18, 716	10.8	38
145	Hypoxia and fibrosis in chronic kidney disease: crossing at pericytes. *Kidney International Supplements*, **2014**, 4, 107-112	6.3	53
144	The authors reply. *Kidney International*, **2014**, 86, 208-9	9.9	
143	The authors reply. *Kidney International*, **2014**, 86, 210	9.9	
142	The high-mobility group protein B1-Toll-like receptor 4 pathway contributes to the acute lung injury induced by bilateral nephrectomy. *Kidney International*, **2014**, 86, 316-26	9.9	47
141	Differences in susceptibility to develop parameters of diabetic nephropathy in four mouse strains with type 1 diabetes. *American Journal of Physiology - Renal Physiology*, **2014**, 306, F1171-8	4.3	13
140	Repulsive guidance cue semaphorin 3A in urine predicts the progression of acute kidney injury in adult patients from a mixed intensive care unit. *Nephrology Dialysis Transplantation*, **2014**, 29, 73-80	4.3	16
139	ANO1: an additional key player in cyst growth. *Kidney International*, **2014**, 85, 1007-9	9.9	9
138	Age and anemia management: relationship of hemoglobin levels with mortality might differ between elderly and nonelderly hemodialysis patients. *Nephrology Dialysis Transplantation*, **2014**, 29, 2316-26	4.3	20
137	A multicenter cross-sectional study of circulating soluble urokinase receptor in Japanese patients with glomerular disease. *Kidney International*, **2014**, 85, 641-8	9.9	66
136	Glyoxalase I reduces glycative and oxidative stress and prevents age-related endothelial dysfunction through modulation of endothelial nitric oxide synthase phosphorylation. *Aging Cell*, **2014**, 13, 519-28	9.9	49
135	Galacto-oligosaccharides attenuate renal injury with microbiota modification. *Physiological Reports*, **2014**, 2, e12029	2.6	35
134	Role of hypoxia in progressive chronic kidney disease and implications for therapy. *Current Opinion in Nephrology and Hypertension*, **2014**, 23, 161-8	3.5	47

133	Development of systemic lupus erythematosus in an elderly male hemodialysis patient with pleuritis. *CEN Case Reports*, **2013**, 2, 46-48	1	1
132	Regulation of hypoxia-inducible factor in kidney disease. *Clinical and Experimental Pharmacology and Physiology*, **2013**, 40, 148-57	3	92
131	Sperm-associated antigen 4, a novel hypoxia-inducible factor 1 target, regulates cytokinesis, and its expression correlates with the prognosis of renal cell carcinoma. *American Journal of Pathology*, **2013**, 182, 2191-203	5.8	24
130	Novel therapeutic strategy with hypoxia-inducible factors via reversible epigenetic regulation mechanisms in progressive tubulointerstitial fibrosis. *Seminars in Nephrology*, **2013**, 33, 375-82	4.8	29
129	Endoplasmic reticulum stress signal impairs erythropoietin production: a role for ATF4. *American Journal of Physiology - Cell Physiology*, **2013**, 304, C342-53	5.4	34
128	Angiogenesis and hypoxia in the kidney. *Nature Reviews Nephrology*, **2013**, 9, 211-22	14.9	87
127	Analysis of genetic and predisposing factors in Japanese patients with atypical hemolytic uremic syndrome. *Molecular Immunology*, **2013**, 54, 238-46	4.3	59
126	Structure-based drug design for hypoxia-inducible factor prolyl-hydroxylase inhibitors and its therapeutic potential for the treatment of erythropoiesis-stimulating agent-resistant anemia: raising expectations for exploratory clinical trials. *Expert Opinion on Drug Discovery*, **2013**, 8, 965-76	6.2	13
125	Oxidative and Endoplasmic Reticulum (ER) Stress in Tissue Fibrosis. *Current Pathobiology Reports*, **2013**, 1, 283-289	2	3
124	A 5-hydroxytryptamine receptor antagonist, sarpogrelate, reduces renal tubulointerstitial fibrosis by suppressing PAI-1. *American Journal of Physiology - Renal Physiology*, **2013**, 305, F1796-803	4.3	20
123	Tissue protection by erythropoietin: new findings in a moving field. *Kidney International*, **2013**, 84, 427-9	9.9	17
122	Indoxyl sulfate signals for rapid mRNA stabilization of Cbp/p300-interacting transactivator with Glu/Asp-rich carboxy-terminal domain 2 (CITED2) and suppresses the expression of hypoxia-inducible genes in experimental CKD and uremia. *FASEB Journal*, **2013**, 27, 4059-75	0.9	40
121	Kidney hypoxia, attributable to increased oxygen consumption, induces nephropathy independently of hyperglycemia and oxidative stress. *Hypertension*, **2013**, 62, 914-9	8.5	103
120	Blocking properdin, the alternative pathway, and anaphylatoxin receptors ameliorates renal ischemia-reperfusion injury in decay-accelerating factor and CD59 double-knockout mice. *Journal of Immunology*, **2013**, 190, 3552-9	5.3	53
119	Recent advances and clinical application of erythropoietin and erythropoiesis-stimulating agents. *Experimental Cell Research*, **2012**, 318, 1068-73	4.2	39
118	Image of Erdheim-Chester disease requiring hemodialysis. *Clinical and Experimental Nephrology*, **2012**, 16, 811-2	2.5	2
117	Dysregulated oxygen metabolism of the kidney by uremic toxins: review. *Journal of Renal Nutrition*, **2012**, 22, 77-80	3	22
116	Dynamic change of chromatin conformation in response to hypoxia enhances the expression of GLUT3 (SLC2A3) by cooperative interaction of hypoxia-inducible factor 1 and KDM3A. *Molecular and Cellular Biology*, **2012**, 32, 3018-32	4.8	167

115	Anthracycline inhibits recruitment of hypoxia-inducible transcription factors and suppresses tumor cell migration and cardiac angiogenic response in the host. *Journal of Biological Chemistry*, **2012**, 287, 34866-34882	5.4	31
114	Downregulation of miR-205 modulates cell susceptibility to oxidative and endoplasmic reticulum stresses in renal tubular cells. *PLoS ONE*, **2012**, 7, e41462	3.7	89
113	Cytoglobin, a novel member of the globin family, protects kidney fibroblasts against oxidative stress under ischemic conditions. *American Journal of Pathology*, **2011**, 178, 128-39	5.8	42
112	Glyoxalase I retards renal senescence. *American Journal of Pathology*, **2011**, 179, 2810-21	5.8	36
111	Pathophysiological response to hypoxia - from the molecular mechanisms of malady to drug discovery: epigenetic regulation of the hypoxic response via hypoxia-inducible factor and histone modifying enzymes. *Journal of Pharmacological Sciences*, **2011**, 115, 453-8	3.7	31
110	Introduction: hearing footsteps of the future. *Clinical and Experimental Pharmacology and Physiology*, **2011**, 38, 438-40	3	0
109	Indoxyl sulfate, a representative uremic toxin, suppresses erythropoietin production in a HIF-dependent manner. *Laboratory Investigation*, **2011**, 91, 1564-71	5.9	113
108	Diary of a Japanese nephrologist during the present disaster. *Kidney International*, **2011**, 79, 1037-9	9.9	9
107	Diary of a Japanese nephrologist during the present disaster: part II. *Kidney International*, **2011**, 80, 3-5	9.9	0
106	Novel Members of the Globin Family and Their Function Against Oxidative Stress **2011**, 105-117		
105	Increased mitochondrial uncoupling results in renal tissue hypoxia and proteinuria. *FASEB Journal*, **2011**, 25, 664.4	0.9	
104	Chronic Interstitial Nephritis **2010**, 748-760		0
103	Indoxyl sulfate inhibits proliferation of human proximal tubular cells via endoplasmic reticulum stress. *American Journal of Physiology - Renal Physiology*, **2010**, 299, F568-76	4.3	60
102	Uremia induces abnormal oxygen consumption in tubules and aggravates chronic hypoxia of the kidney via oxidative stress. *American Journal of Physiology - Renal Physiology*, **2010**, 299, F380-6	4.3	60
101	Forewarned is forearmed: arm with HIF activation. *Nephrology Dialysis Transplantation*, **2010**, 25, 1385-7	4.3	4
100	Cytoglobin, a novel globin, plays an antifibrotic role in the kidney. *American Journal of Physiology - Renal Physiology*, **2010**, 299, F1120-33	4.3	39
99	The suffocating kidney: tubulointerstitial hypoxia in end-stage renal disease. *Nature Reviews Nephrology*, **2010**, 6, 667-78	14.9	198
98	The role of hypoxia, increased oxygen consumption, and hypoxia-inducible factor-1 alpha in progression of chronic kidney disease. *Current Opinion in Nephrology and Hypertension*, **2010**, 19, 43-50	3.5	57

97	The role of glyoxalase system in renal hypoxia. *Advances in Experimental Medicine and Biology*, **2010**, 662, 49-55	3.6	15
96	Metallothionein is upregulated by hypoxia and stabilizes hypoxia-inducible factor in the kidney. *Kidney International*, **2009**, 75, 268-77	9.9	42
95	Endoplasmic reticulum stress induces autophagy in renal proximal tubular cells. *Nephrology Dialysis Transplantation*, **2009**, 24, 2665-72	4.3	87
94	Glyoxalase I overexpression ameliorates renal ischemia-reperfusion injury in rats. *American Journal of Physiology - Renal Physiology*, **2009**, 296, F912-21	4.3	75
93	Drug discovery for overcoming chronic kidney disease (CKD): prolyl-hydroxylase inhibitors to activate hypoxia-inducible factor (HIF) as a novel therapeutic approach in CKD. *Journal of Pharmacological Sciences*, **2009**, 109, 24-31	3.7	32
92	Novel therapeutic approach targeting the HIF-HRE system in the kidney. *Advances in Experimental Medicine and Biology*, **2009**, 645, 81-6	3.6	7
91	Hypoxia and hypoxia-inducible factor in renal disease. *Nephron Experimental Nephrology*, **2008**, 110, e1-7		71
90	Albumin suppresses vascular endothelial growth factor via alteration of hypoxia-inducible factor/hypoxia-responsive element pathway. *Biochemical and Biophysical Research Communications*, **2008**, 367, 305-10	3.4	19
89	Validation of an autotaxin enzyme immunoassay in human serum samples and its application to hypoalbuminemia differentiation. *Clinica Chimica Acta*, **2008**, 388, 51-8	6.2	84
88	Hemoglobin is expressed by mesangial cells and reduces oxidant stress. *Journal of the American Society of Nephrology: JASN*, **2008**, 19, 1500-8	12.7	106
87	Chronic hypoxia aggravates renal injury via suppression of Cu/Zn-SOD: a proteomic analysis. *American Journal of Physiology - Renal Physiology*, **2008**, 294, F62-72	4.3	35
86	Inhibition of plasminogen activator inhibitor-1: its mechanism and effectiveness on coagulation and fibrosis. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2008**, 28, 672-7	9.4	105
85	Preconditioning with endoplasmic reticulum stress ameliorates mesangioproliferative glomerulonephritis. *Journal of the American Society of Nephrology: JASN*, **2008**, 19, 915-22	12.7	83
84	Activation of the renin-angiotensin system and chronic hypoxia of the kidney. *Hypertension Research*, **2008**, 31, 175-84	4.7	72
83	The role of megsin, a serine protease inhibitor, in diabetic mesangial matrix accumulation. *Kidney International*, **2008**, 74, 768-74	9.9	11
82	Cobalt ameliorates renal injury in an obese, hypertensive type 2 diabetes rat model. *Nephrology Dialysis Transplantation*, **2008**, 23, 1166-72	4.3	103
81	Role of chronic hypoxia and hypoxia inducible factor in kidney disease. *Chinese Medical Journal*, **2008**, 121, 257-64	2.9	4
80	Protective role of hypoxia-inducible factor-2alpha against ischemic damage and oxidative stress in the kidney. *Journal of the American Society of Nephrology: JASN*, **2007**, 18, 1218-26	12.7	105

79	A novel class of prolyl hydroxylase inhibitors induces angiogenesis and exerts organ protection against ischemia. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2007**, 27, 2548-54	9.4	104
78	Hypoxia and the HIF system in kidney disease. *Journal of Molecular Medicine*, **2007**, 85, 1325-30	5.5	162
77	Pathogenesis and prognosis of thrombotic microangiopathy. *Clinical and Experimental Nephrology*, **2007**, 11, 107-114	2.5	16
76	Erythropoietin induces heme oxygenase-1 expression and attenuates oxidative stress. *Biochemical and Biophysical Research Communications*, **2007**, 359, 928-34	3.4	71
75	The intrarenal renin-angiotensin system: from physiology to the pathobiology of hypertension and kidney disease. *Pharmacological Reviews*, **2007**, 59, 251-87	22.5	930
74	Angiotensin-induced hypoxia in the kidney: functional and structural changes of the renal circulation. *Advances in Experimental Medicine and Biology*, **2007**, 618, 85-99	3.6	12
73	Hypoxia and expression of hypoxia-inducible factor in the aging kidney. *Journals of Gerontology - Series A Biological Sciences and Medical Sciences*, **2006**, 61, 795-805	6.4	79
72	Novel drugs and the response to hypoxia: HIF stabilizers and prolyl hydroxylase. *Recent Patents on Cardiovascular Drug Discovery*, **2006**, 1, 129-39		27
71	Pathophysiological Roles of Renin-Angiotensin System on Erythropoietic Action. *Current Hypertension Reviews*, **2006**, 2, 325-331	2.3	
70	A severe diabetic nephropathy model with early development of nodule-like lesions induced by megsin overexpression in RAGE/iNOS transgenic mice. *Diabetes*, **2006**, 55, 356-66	0.9	73
69	High glucose blunts vascular endothelial growth factor response to hypoxia via the oxidative stress-regulated hypoxia-inducible factor/hypoxia-responsible element pathway. *Journal of the American Society of Nephrology: JASN*, **2006**, 17, 1405-13	12.7	103
68	Clinical outcome of thrombotic microangiopathy after living-donor liver transplantation treated with plasma exchange therapy. *Clinical Journal of the American Society of Nephrology: CJASN*, **2006**, 1, 811-9	6.9	18
67	Pathogenesis of renal anemia. *Seminars in Nephrology*, **2006**, 26, 261-8	4.8	123
66	Chronic hypoxia and tubulointerstitial injury: a final common pathway to end-stage renal failure. *Journal of the American Society of Nephrology: JASN*, **2006**, 17, 17-25	12.7	829
65	Cellular and molecular biology of membranous nephropathy. *Journal of Nephrology*, **2006**, 19, 699-705	4.8	30
64	Cellular response to injury in membranous nephropathy. *Journal of the American Society of Nephrology: JASN*, **2005**, 16, 1195-204	12.7	150
63	Synergistic contributions of carbonyl stress and megsin in diabetic nephropathy. *Annals of the New York Academy of Sciences*, **2005**, 1043, 605-8	6.5	2
62	A biologic role of HIF-1 in the renal medulla. *Kidney International*, **2005**, 67, 1428-39	9.9	54

61	Involvement of endoplasmic reticulum (ER) stress in podocyte injury induced by excessive protein accumulation. *Kidney International*, **2005**, 68, 2639-50	9.9	83
60	Induction of protective genes by cobalt ameliorates tubulointerstitial injury in the progressive Thy1 nephritis. *Kidney International*, **2005**, 68, 2714-25	9.9	95
59	Cobalt promotes angiogenesis via hypoxia-inducible factor and protects tubulointerstitium in the remnant kidney model. *Laboratory Investigation*, **2005**, 85, 1292-307	5.9	181
58	Mechanisms of immune-deposit formation and the mediation of immune renal injury. *Clinical and Experimental Nephrology*, **2005**, 9, 183-91	2.5	119
57	Hypoxia-inducible factor modulates tubular cell survival in cisplatin nephrotoxicity. *American Journal of Physiology - Renal Physiology*, **2005**, 289, F1123-33	4.3	82
56	Renoprotective properties of angiotensin receptor blockers beyond blood pressure lowering. *Journal of the American Society of Nephrology: JASN*, **2005**, 16, 3631-41	12.7	162
55	In a type 2 diabetic nephropathy rat model, the improvement of obesity by a low calorie diet reduces oxidative/carbonyl stress and prevents diabetic nephropathy. *Nephrology Dialysis Transplantation*, **2005**, 20, 2661-9	4.3	58
54	Enhanced erythropoiesis mediated by activation of the renin-angiotensin system via angiotensin II type 1a receptor. *FASEB Journal*, **2005**, 19, 2023-5	0.9	86
53	Renoprotection with Anti-Hypertensives: Reduction of Proteinuria and Improvement of Oxygenation via Inhibition of the Renin-Angiotensin System. *Current Hypertension Reviews*, **2005**, 1, 67-76	2.3	5
52	Protection of endothelial cells by dextran sulfate in rats with thrombotic microangiopathy. *Journal of the American Society of Nephrology: JASN*, **2005**, 16, 2997-3005	12.7	11
51	Blockade of calcium influx through L-type calcium channels attenuates mitochondrial injury and apoptosis in hypoxic renal tubular cells. *Journal of the American Society of Nephrology: JASN*, **2004**, 15, 2320-33	12.7	69
50	Evidence of tubular hypoxia in the early phase in the remnant kidney model. *Journal of the American Society of Nephrology: JASN*, **2004**, 15, 1277-88	12.7	193
49	Accelerated glomerular injury in hemi-nephrectomized transgenic mice of mesangial cell-predominant serpin, megsin. *Nephron Experimental Nephrology*, **2004**, 96, e127-33		4
48	Hypoxia and tubulointerstitial injury: a final common pathway to end-stage renal failure. *Nephron Experimental Nephrology*, **2004**, 98, e8-12		81
47	Critical protection from renal ischemia reperfusion injury by CD55 and CD59. *Journal of Immunology* , **2004**, 172, 3869-75	5.3	141
46	Hypoperfusion of peritubular capillaries induces chronic hypoxia before progression of tubulointerstitial injury in a progressive model of rat glomerulonephritis. *Journal of the American Society of Nephrology: JASN*, **2004**, 15, 1574-81	12.7	135
45	Transdifferentiation of cultured tubular cells induced by hypoxia. *Kidney International*, **2004**, 65, 871-80	9.9	153
44	Hypoxia in renal disease with proteinuria and/or glomerular hypertension. *American Journal of Pathology*, **2004**, 165, 1979-92	5.8	90

43	Mechanisms of tubulointerstitial injury in the kidney: final common pathways to end-stage renal failure. *Internal Medicine*, **2004**, 43, 9-17	1.1	258
42	Induction of renoprotective gene expression by cobalt ameliorates ischemic injury of the kidney in rats. *Journal of the American Society of Nephrology: JASN*, **2003**, 14, 1825-32	12.7	218
41	Imbalance of T-cell subsets in angiotensin II-infused hypertensive rats with kidney injury. *Hypertension*, **2003**, 42, 31-8	8.5	171
40	Clinical and psychological aspects of restless legs syndrome in uremic patients on hemodialysis. *American Journal of Kidney Diseases*, **2003**, 41, 833-9	7.4	112
39	Hypoxia-induced apoptosis in cultured glomerular endothelial cells: involvement of mitochondrial pathways. *Kidney International*, **2003**, 64, 2020-32	9.9	54
38	Anti-hypertensive agents inhibit in vivo the formation of advanced glycation end products and improve renal damage in a type 2 diabetic nephropathy rat model. *Journal of the American Society of Nephrology: JASN*, **2003**, 14, 1212-22	12.7	147
37	Hypoxia induces apoptosis in SV40-immortalized rat proximal tubular cells through the mitochondrial pathways, devoid of HIF1-mediated upregulation of Bax. *Biochemical and Biophysical Research Communications*, **2003**, 309, 222-31	3.4	60
36	Efficient in vitro lowering of carbonyl stress by the glyoxalase system in conventional glucose peritoneal dialysis fluid. *Kidney International*, **2002**, 62, 679-87	9.9	32
35	ET(B) receptor protects the tubulointerstitium in experimental thrombotic microangiopathy. *Kidney International*, **2002**, 62, 922-8	9.9	14
34	In vivo klotho gene transfer ameliorates angiotensin II-induced renal damage. *Hypertension*, **2002**, 39, 838-43	8.5	210
33	Transcriptional regulation of a mesangium-predominant gene, megsin. *Journal of the American Society of Nephrology: JASN*, **2002**, 13, 2715-22	12.7	9
32	Contribution of genetically engineered animals to the analyses of complement in the pathogenesis of nephritis. *Nephrology Dialysis Transplantation*, **2002**, 17 Suppl 9, 34-6	4.3	8
31	Angiotensin II receptor antagonists and angiotensin-converting enzyme inhibitors lower in vitro the formation of advanced glycation end products: biochemical mechanisms. *Journal of the American Society of Nephrology: JASN*, **2002**, 13, 2478-87	12.7	250
30	Glucose Dialysate Induces Mitochondrial DNA Damage in Peritoneal Mesothelial Cells. *Peritoneal Dialysis International*, **2002**, 22, 11-21	2.8	36
29	Overexpression of the serpin megsin induces progressive mesangial cell proliferation and expansion. *Journal of Clinical Investigation*, **2002**, 109, 585-593	15.9	32
28	C6 mediates chronic progression of tubulointerstitial damage in rats with remnant kidneys. *Journal of the American Society of Nephrology: JASN*, **2002**, 13, 928-936	12.7	91
27	Overexpression of the serpin megsin induces progressive mesangial cell proliferation and expansion. *Journal of Clinical Investigation*, **2002**, 109, 585-93	15.9	16
26	Glyoxalase I deficiency is associated with an unusual level of advanced glycation end products in a hemodialysis patient. *Kidney International*, **2001**, 60, 2351-9	9.9	78

25	Cloning of rodent megsin revealed its up-regulation in mesangioproliferative nephritis. *Kidney International*, **2001**, 60, 641-52	9.9	15
24	Increased susceptibility of decay-accelerating factor deficient mice to anti-glomerular basement membrane glomerulonephritis. *Journal of Immunology*, **2001**, 167, 2791-7	5.3	72
23	Protective role of nitric oxide in a model of thrombotic microangiopathy in rats. *Journal of the American Society of Nephrology: JASN*, **2001**, 12, 2088-2097	12.7	34
22	Cloning and characterization of a novel subunit of protein serine/threonine phosphatase 4 from mesangial cells. *Journal of the American Society of Nephrology: JASN*, **2001**, 12, 2601-2608	12.7	19
21	C5b-9 membrane attack complex mediates endothelial cell apoptosis in experimental glomerulonephritis. *American Journal of Physiology - Renal Physiology*, **2000**, 278, F747-57	4.3	64
20	Crry, a complement regulatory protein, modulates renal interstitial disease induced by proteinuria. *Kidney International*, **1999**, 56, 2096-106	9.9	41
19	Complement membrane attack complex (C5b-9) mediates interstitial disease in experimental nephrotic syndrome. *Journal of the American Society of Nephrology: JASN*, **1999**, 10, 2323-31	12.7	136
18	Expression of megsin mRNA, a novel mesangium-predominant gene, in the renal tissues of various glomerular diseases. *Journal of the American Society of Nephrology: JASN*, **1999**, 10, 2606-13	12.7	30
17	Complement regulatory proteins in glomerular diseases. *Kidney International*, **1998**, 54, 1419-28	9.9	81
16	The plasma membrane-actin linking protein, ezrin, is a glomerular epithelial cell marker in glomerulogenesis, in the adult kidney and in glomerular injury. *Kidney International*, **1998**, 54, 1934-44	9.9	50
15	Functional quantitative analysis of the genome in cultured human mesangial cells. Technical note. *Kidney International*, **1998**, 53, 154-8	9.9	20
14	Renal catabolism of advanced glycation end products: the fate of pentosidine. *Kidney International*, **1998**, 53, 416-22	9.9	165
13	Increased pentosidine, an advanced glycation end product, in plasma and synovial fluid from patients with rheumatoid arthritis and its relation with inflammatory markers. *Biochemical and Biophysical Research Communications*, **1998**, 244, 45-9	3.4	129
12	A new model of renal microvascular injury. *Current Opinion in Nephrology and Hypertension*, **1998**, 7, 457-62	3.5	12
11	Molecular mechanisms of experimental glomerulonephritis: an overview. *Nephrology*, **1997**, 3, s633-s637	2.2	5
10	Mesangial cell proliferation mediated by PDGF and bFGF is determined by levels of the cyclin kinase inhibitor p27Kip1. *Kidney International*, **1997**, 51, 1088-99	9.9	79
9	A new model of renal microvascular endothelial injury. *Kidney International*, **1997**, 52, 182-94	9.9	56
8	Cyclin kinase inhibitors are increased during experimental membranous nephropathy: potential role in limiting glomerular epithelial cell proliferation in vivo. *Kidney International*, **1997**, 52, 404-13	9.9	97

7	Renal microvascular injury induced by antibody to glomerular endothelial cells is mediated by C5b-9. *Kidney International*, **1997**, 52, 1570-8	9.9	34
6	Transfected CD59 protects mesangial cells from injury induced by antibody and complement. *Kidney International*, **1996**, 50, 257-66	9.9	21
5	Changes in cell-cycle protein expression during experimental mesangial proliferative glomerulonephritis. *Kidney International*, **1996**, 50, 1230-9	9.9	79
4	Beneficial effects of systemic immunoglobulin in experimental membranous nephropathy. *Kidney International*, **1996**, 50, 2054-62	9.9	25
3	KIF1B, a novel microtubule plus end-directed monomeric motor protein for transport of mitochondria. *Cell*, **1994**, 79, 1209-20	56.2	491
2	Hypophosphatasia in an adult: a case report. *Japanese Journal of Medicine*, **1991**, 30, 47-52		6
1	Mitochondrial Damage Causes Inflammation Via cGAS-STING Signaling in Acute Kidney Injury. *SSRN Electronic Journal*,	1	2